The IO agents, particularly anti‐PD‐1/PD‐L1 antibodies, have likely contributed to the improving response rates due to their ability to induce anti‐cancer immunity and durable anti‐tumor responses, albeit only in select patients and tumor types.27, 28, 29, 30, 31, 32. Here, CD274 is linked to cancer.